Table 6 Results of logistic regression model showing the reported use of SRS * as part of treatment for brain metastases according to multiple clinical, sociodemographic, and practice setting factors 2
Including SRS1 | p-value | |
|---|---|---|
Lesions | ||
1 (reference) | 1.00 | |
3 | 2.22 (1.96-2.51) | <.0001 |
8 | 0.19 (0.15-0.23) | <.0001 |
Karnofsky Performance Status | ||
80 (reference) | 1.00 | |
50 | 0.38 (0.31-0.46) | <.0001 |
Tumor Characteristics | ||
Lung cancer (reference) | 1.00 | |
Melanoma histology | 2.84 (2.45-3.29) | <.0001 |
Extracranial disease | ||
No extracranial disease (reference) | 1.00 | |
Active extracranial disease | 0.56 (0.47-0.65) | <.0001 |
Age | ||
55 (reference) | 1.00 | |
80 | 1.23 (1.07-1.41) | 0.0034 |
Focal neurological deficits | ||
None (reference) | 1.00 | |
Present | 0.99 (0.85-1.14) | 0.8492 |
Lesion size | ||
Small (reference) | 1.00 | |
Large | 0.58 (0.47-0.71) | <.0001 |
Race | ||
Other (reference) | 1.00 | |
White | 1.13 (0.83-1.52) | 0.4415 |
Gender | ||
Male (reference) | 1.00 | |
Female | 1.07 (0.81-1.40) | 0.6287 |
Specialization of Practice Setting | ||
Multispecialty (reference) | 1.00 | |
Single | 1.07 (0.82-1.39) | 0.6036 |
Access to SRS | ||
None (reference) | 1.00 | |
Personal use | 3.57 (2.42-5.26) | <.0001 |
Available in practice | 2.22 (1.46-3.37) | 0.0002 |
WBRT † Adverse Effects Severity | ||
None (reference) | 1.00 | |
At least minimal severity | 0.55 (0.40-0.77) | 0.0004 |
SRS Adverse Effects Severity | ||
None (reference) | 1.00 | |
At least minimal severity | 0.90 (0.53-1.51) | 0.6804 |
Personal Experience with Brain Metastases | ||
Some personal (reference) 3 | 1.00 | |
Patients only | 1.10 (0.81-1.50) | 0.5369 |